Nwam LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 87.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,619 shares of the company’s stock after acquiring an additional 3,091 shares during the quarter. Nwam LLC’s holdings in AstraZeneca were worth $386,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Renaissance Technologies LLC lifted its position in AstraZeneca by 3,313.2% in the 3rd quarter. Renaissance Technologies LLC now owns 6,884,376 shares of the company’s stock worth $413,476,000 after buying an additional 6,682,676 shares in the last quarter. Wellington Management Group LLP boosted its position in AstraZeneca by 9.3% during the third quarter. Wellington Management Group LLP now owns 53,145,564 shares of the company’s stock valued at $3,191,923,000 after purchasing an additional 4,526,346 shares during the last quarter. Hsbc Holdings PLC grew its stake in AstraZeneca by 295.1% in the third quarter. Hsbc Holdings PLC now owns 5,895,240 shares of the company’s stock valued at $355,716,000 after purchasing an additional 4,403,238 shares in the last quarter. Franklin Resources Inc. increased its position in AstraZeneca by 59.6% in the 3rd quarter. Franklin Resources Inc. now owns 9,524,576 shares of the company’s stock worth $572,045,000 after purchasing an additional 3,556,457 shares during the last quarter. Finally, Putnam Investments LLC raised its stake in shares of AstraZeneca by 50.0% during the 3rd quarter. Putnam Investments LLC now owns 7,062,272 shares of the company’s stock worth $424,160,000 after purchasing an additional 2,354,345 shares in the last quarter. Institutional investors and hedge funds own 20.46% of the company’s stock.
AZN has been the subject of several analyst reports. TheStreet raised shares of AstraZeneca from a “c+” rating to a “b-” rating in a research note on Thursday, March 10th. Credit Suisse Group upped their price target on AstraZeneca from GBX 9,000 ($110.95) to £110 ($135.60) in a research note on Friday, April 8th. Deutsche Bank Aktiengesellschaft raised their price objective on AstraZeneca from £105 ($129.44) to £115 ($141.77) in a research note on Wednesday, April 6th. SVB Leerink upped their target price on AstraZeneca from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, February 24th. Finally, Barclays lifted their price target on shares of AstraZeneca from £115 ($141.77) to £120 ($147.93) in a research report on Thursday, April 14th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7,223.13.
AstraZeneca (NASDAQ:AZN – Get Rating) last announced its earnings results on Friday, April 29th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.09. The business had revenue of $11.39 billion during the quarter, compared to analysts’ expectations of $10.96 billion. AstraZeneca had a negative net margin of 2.56% and a positive return on equity of 26.29%. The firm’s revenue for the quarter was up 55.6% on a year-over-year basis. During the same quarter last year, the company posted $0.81 EPS. On average, sell-side analysts forecast that AstraZeneca PLC will post 3.34 EPS for the current fiscal year.
AstraZeneca Profile (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.